EC Pulmonology and Respiratory Medicine

Research Article Volume 14 Issue 9 - 2025

Long-Term Lung Sequelae of COVID-19

Baimakanova GE1*, Samsonova MV1,2, Chernyaev AL2,3,4, Kontorschikov AV3 and Belevsky AS4

1State Budgetary Institution of Healthcare of the City of Moscow "Moscow Clinical Scientific and Practical Center Named After A.S. Loginov of the Moscow City Health Department", Moscow, Russia

2Federal State Budgetary Institution “Research Institute of Pulmonology” of the Federal Medical and Biological Agency of Russia, Moscow, Orekhovy Boulevard, Russia

3Federal State Budgetary Scientific Institution Research Institute of Human Morphology, Moscow, Russia

4Federal State Autonomous Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation, Moscow, Russia

*Corresponding Author: Baimakanova GE, State Budgetary Institution of Healthcare of the City of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Moscow City Health Department", Moscow, Russia.
Received: July 21, 2025; Published: August 13, 2025




Introduction: We studied the clinical and histological profile of lung tissue in patients with persistent pulmonary disease, respiratory symptoms and computed tomography (CT) findings after SARS-CoV-2 infection.

Materials and Methods: The study included 15 patients (7 females and 8 males) with a mean age of 57.7 years. All patients underwent laboratory tests, chest CT, echocardiography, and pulmonary function tests (PFT). Pulmonary tissue and bronchoalveolar lavage (BAL) samples were obtained by fibrobronchoscopy (FBS), transbronchial (TB) forceps (2 patients), and lung cryobiopsy (11 patients); open biopsy was performed in 2 patients. Cellular composition, DNA of herpesvirus, Mycobacterium tuberculosis complex and galactomannan optical density index, bacterial and fungal microflora growth were determined in BAL. SARS-CoV-2 was also identified in samples from the nasal mucosa, throat, BAL and feces using a polymerase chain reaction (PCR).

Results: The results showed no true pulmonary fibrosis in patients recovered from SARS-CoV-2 infection with persistent respiratory symptoms, functional impairment, and CT findings after SARS-CoV-2 infection.

Conclusion: Thus, no true pulmonary fibrosis was found in patients after SARS-CoV-2 infection with persistent respiratory symptoms, functional impairment, and CT findings. The observed changes comply with the current and/or resolving infection and inflammatory process.

 Keywords: SARS-COV2; Interstitial Pneumonia; Pulmonary Fibrosis

  1. WHO coronavirus disease (COVID-19) dashboard (2025).
  2. Soriano JB., et al. “WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus”. Lancet Infectious Diseases 4 (2022): e102-e107.
  3. Chuchalin AG. “COVID-19 and human safety”. Terapevticheskii Arkhiv3 (2021): 253-254.
  4. Lizinfeld IA., et al. “Assessing factors influencing the likelihood of hospitalization of COVID-19 patients with concomitant pathologies and developing a prognostic model based on them”. Terapevticheskii Arkhiv1 (2022): 57-63.
  5. Chuchalin AG. “Pulmonary fibrosis in patients who have had COVID-19”. Terapevticheskii Arkhiv11 (2022): 1333-1339.
  6. Avdeev SN., et al. “Profilaktika, diagnostika i lecheniie novoi koronavirusnoi infektsii (COVID-19): vremennyie metodicheskiie rekomendatsii”. Versiia 15, Moscow (2022).
  7. Mannanova IV., et al. “Clinical and laboratory characteristics of COVID-19”. RMJ 4 (2021): 22-25.
  8. Maleev VV., et al. “Modern concepts of cerebral dysfunction at COVID-19”. Infectious Diseases3 (2021): 109-115.
  9. Seeßle J., et al. “Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): A prospective cohort study”. Clinical Infectious Diseases7 (2022): 1191-1198.
  10. Rivera-Izquierdo M., et al. “Long COVID 12 months after discharge: persistent symptoms in patients hospitalised due to COVID-19 and patients hospitalised due to other causes - a multicentre cohort study”. BMC Medicine1 (2022): 92.
  11. Liu T., et al. “Twelve-month systemic consequences of coronavirus disease 2019 (COVID-19) in patients discharged from hospital: A prospective cohort study in Wuhan, China”. Clinical Infectious Diseases 11 (2022): 1953-1965.
  12. Huang L., et al. “Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study”. Lancet Respiratory Medicine9 (2022): 863-876.
  13. Chen Y., et al. “One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection”. BMC Medicine 1 (2021): 191.
  14. Han X., et al. “Fibrotic interstitial lung abnormalities at 1-year follow-up CT after severe COVID-19”. Radiology3 (2021): E438-E440.
  15. Pan F., et al. “Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19”. Radiology 3 (2022): 709-719.
  16. Luger AK., et al. “Chest CT of lung injury 1 year after covid-19 pneumonia: The CovILD study”. Radiology2 (2022): 462-470.
  17. Eberst G., et al. “Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia”. Annals of Intensive Care 1 (2022): 23.
  18. Vijayakumar B., et al. “CT lung abnormalities after COVID-19 at 3 months and 1 year after hospital discharge”. Radiology2 (2022): 444-454.
  19. Bocchino M., et al. “Chest CT-based assessment of 1-year outcomes after moderate COVID-19 pneumonia”. Radiology2 (2022): 479-485.
  20. Guler SA., et al. “Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study”. European Respiratory Journal 4 (2021): 2003690.
  21. van Gassel RJJ., et al. “High prevalence of pulmonary sequelae at 3 months after hospital discharge in mechanically ventilated survivors of COVID-19”. American Journal of Respiratory and Critical Care Medicine 3 (2021): 371-374.
  22. Caruso D., et al. “Post-acute sequelae of COVID-19 pneumonia: six-month chest CT follow-up”. Radiology2 (2021): E396-E405.
  23. Ravaglia C., et al. “Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection”. European Respiratory Journal 4 (2022): 2102411.
  24. Aesif SW., et al. “Pulmonary pathology of covid-19 following 8 weeks to 4 months of severe disease: a report of three cases, including one with bilateral lung transplantation”. American Journal of Clinical Pathology 4 (2021): 506-514.
  25. Konopka KE Perry., et al. “Usual interstitial pneumonia is the most common finding in surgical lung biopsies from patients with persistent interstitial lung disease following infection with SARS-CoV-2”. EClinicalMedicine 42 (2021): 101209.
  26. Swank Z., et al. “Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae”. Clinical Infectious Diseases 3 (2023): e487-e490.
  27. Proal AD and VanElzakker MB. “Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms”. Frontiers in Microbiology 12 (2021): 698169.
  28. Phetsouphanh C., et al. “Immunological dysfunction persists for 8 months following initial mild-to moderate SARS-CoV-2 infection”. Nature Immunology 2 (2022): 210-216.
  29. Zubchenko S., et al. “Herpesvirus infections and postCOVID-19 manifestations: a pilot observational study”. Rheumatology International9 (2022): 1523-1530.
  30. Liu Q., et al. “Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome”. Gut3 (2022): 544-552.
  31. Yeoh YK., et al. “Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19”. Gut 4 (2021): 698-706.
  32. Wallukat G., et al. “Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms”. Journal of Translational Autoimmunity 4 (2021): 100100.
  33. Su Y., et al. “Multiple early factors anticipate post-acute COVID-19 sequelae”. Cell5 (2022): 881-895.e20.
  34. Arthur JM., et al. “Development of ACE2 autoantibodies after SARS-CoV-2 infection”. PLoS One9 (2021): e0257016.
  35. Charfeddine S., et al. “Long COVID-19 syndrome: is it related to microcirculation and endothelial dysfunction? insights from TUN-EndCOV Study”. Frontiers in Cardiovascular Medicine 8 (2021): 745758.
  36. Pretorius E., et al. “Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)”. Cardiovascular Diabetology 1 (2022): 148.
  37. Spudich S and Nath A. “Nervous system consequences of COVID-19”. Science6578 (2022): 267-269.
  38. Ehab A., et al. “Transbronchial lung cryobiopsy performed in acute COVID-19 pneumonia: first report”. Advances in Respiratory Medicine1 (2021): 72-74.
  39. De Gopegui Miguelena PR., et al. “Afectación endotelial por Covid-19 en criobiopsia pulmonar”. Archivos de Bronconeumología 57 (2020): 65.
  40. Doglioni C., et al. “Acute Lung injury evolution in Covid-19”. MedRxiv (2020).
  41. Barisione E., et al. “Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems”. Virchows Archiv 3 (2021): 471-485.
  42. Su Y., et al. “Multiple early factors anticipate post-acute COVID-19 sequelae”. Cell 5 (2022): 881-895.e20.
  43. Bastard P., et al. “Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths”. Science Immunology 62 (2021): eabl4340.
  44. Wang C., et al. “COVID-19 in early 2021: current status and looking forward”. Signal Transduction and Targeted Therapy 1 (2021): 114.
  45. Bone RC. “Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation”. Critical Care Medicine 1 (1996): 163-172.
  46. Chang S., et al. “Mobility network models of COVID-19 explain inequities and inform reopening”. Nature 7840 (2021): 82-87.
  47. Parasa S., et al. “Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis”. JAMA Network Open 6 (2020): e2011335.
  48. Hotchkiss RS., et al. “Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach”. Lancet Infectious Diseases 3 (2013): 260-268.
  49. Sugimoto MA., et al. “Resolution of inflammation: what controls its onset?” Frontiers in Immunology 7 (2016): 160.
  50. Bozza FA., et al. “Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis”. Critical Care 2 (2007): R49.
  51. Pretorius L., et al. “Iron dysregulation and dormant microbes as causative agents for impaired blood rheology and pathological clotting in Alzheimer's type dementia”. Frontiers in Neuroscience 12 (2018): 851.
  52. Fitridge R and Thompson M. “Mechanisms of vascular disease: A reference book for vascular specialists”. Adelaide (AU): University of Adelaide Press (2011).
  53. Hamers L., et al. “Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options”. Minerva Anestesiologica 4 (2015): 426-439.
  54. Walton AH., et al. “Reactivation of multiple viruses in patients with sepsis”. PLoS One2 (2014): e98819.
  55. Xu K., et al. “Management of COVID-19: the Zhejiang experience”. Zhejiang Da Xue Xue Bao Yi Xue Ban 2 (2020): 147-157.
  56. Baek MS., et al. “Clinical and radiological findings of adult hospitalized patients with community-acquired pneumonia from SARS-CoV-2 and endemic human coronaviruses”. PLoS One1 (2021): e0245547.
  57. Di Felice G., et al. “Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients”. Elife 11 (2022): e74634.
  58. Wei J., et al. “Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection”. Cell1 (2021): 76-91.e13.
  59. Truong TT J., et al. “Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series”. EBioMedicine 67 (2021): 103355.
  60. Choi B., et al. “Persistence and evolution of SARS-CoV-2 in an immunocompromised host”. New England Journal of Medicine 23 (2020): 2291-2293.
  61. Obeid M., et al. “Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients”. JAMA Oncology5 (2022): e220446.
  62. Sjöwall J., et al. “SARS-CoV-2 antibody isotypes in systemic lupus erythematosus patients prior to vaccination: associations with disease activity, antinuclear antibodies, and immunomodulatory drugs during the first year of the pandemic”. Frontiers in Immunology 12 (2021): 724047.
  63. Huang L., et al. “Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study”. Lancet Respiratory Medicine 9 (2022): 863-876.
  64. Moss P. “The T cell immune response against SARS-CoV-2”. Nature Immunology 2 (2022): 186-193.
  65. Mohanraj D., et al. “Antibody responses to SARSCoV-2 infection-comparative determination of seroprevalence in two high-throughput assays versus a sensitive spike protein ELISA”. Vaccines (Basel)11 (2021): 1310.
  66. Sherina N., et al. “Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection”. Medicine 3 (2021): 281-295.e4.
  67. Jung JH., et al. “SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells”. Nature Communications 1 (2021): 4043.
  68. Zuo J., et al. “Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection”. Nature Immunology 5 (2021): 620-626.
  69. Izadi Z., et al. “Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19”. JAMA Network Open 10 (2021): e2129639.
  70. Ahmed H., et al. “Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis”. Journal of Rehabilitation Medicine 5 (2020): jrm00063.
  71. Marvisi M., et al. “First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution”. International Journal of Infectious Diseases 99 (2020): 485-488.
  72. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
  73. Ojo AS., et al. “Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies”. BMC Pulmonary Medicine (2020): 6175964.
  74. Gao YD., et al. “Risk factors for severe and critically ill COVID-19 patients: A review”. Allergy2 (2021): 428-455.
  75. Hu ZJ., et al. “Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients”. Frontiers in Immunology 11 (2020): 585647.

Baimakanova GE., et al. “Long-Term Lung Sequelae of COVID-19”. EC Pulmonology and Respiratory Medicine  14.9 (2025): 01-16.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net